188 related articles for article (PubMed ID: 11495074)
1. High-dose proton-pump inhibitors as a diagnostic test of gastro-oesophageal reflux disease in endoscopic-negative patients.
Juul-Hansen P; Rydning A; Jacobsen CD; Hansen T
Scand J Gastroenterol; 2001 Aug; 36(8):806-10. PubMed ID: 11495074
[TBL] [Abstract][Full Text] [Related]
2. The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial.
Bautista J; Fullerton H; Briseno M; Cui H; Fass R
Aliment Pharmacol Ther; 2004 May; 19(10):1123-30. PubMed ID: 15142202
[TBL] [Abstract][Full Text] [Related]
3. Endoscopy-negative reflux disease: what is the value of a proton-pump inhibitor test in everyday clinical practice?
Juul-Hansen P; Rydning A
Scand J Gastroenterol; 2003 Dec; 38(12):1200-3. PubMed ID: 14750637
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
Hatlebakk JG; Berstad A
Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
[TBL] [Abstract][Full Text] [Related]
5. Speed of onset of oesophageal acid reduction with different proton-pump inhibitors in patients with reflux oesophagitis.
Newton M; Burnham WR; Kamm MA
Eur J Gastroenterol Hepatol; 1998 Sep; 10(9):753-8. PubMed ID: 9831269
[TBL] [Abstract][Full Text] [Related]
6. Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood.
Franco MT; Salvia G; Terrin G; Spadaro R; De Rosa I; Iula VD; Cucchiara S
Dig Liver Dis; 2000 Nov; 32(8):660-6. PubMed ID: 11142573
[TBL] [Abstract][Full Text] [Related]
7. The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial.
Dickman R; Emmons S; Cui H; Sewell J; Hernández D; Esquivel RF; Fass R
Aliment Pharmacol Ther; 2005 Sep; 22(6):547-55. PubMed ID: 16167971
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of potent acid inhibition in gastro-oesophageal reflux disease.
Monés J
Drugs; 2005; 65 Suppl 1():35-42. PubMed ID: 16335856
[TBL] [Abstract][Full Text] [Related]
9. Double-blind, randomized controlled study to assess the effects of lansoprazole 30 mg and lansoprazole 15 mg on 24-h oesophageal and intragastric pH in Chinese subjects with gastro-oesophageal reflux disease.
Wong WM; Lai KC; Hui WM; Lam KF; Huang JQ; Hu WH; Wong NY; Lam CL; Xia HH; Chan AO; Lam SK; Wong BC
Aliment Pharmacol Ther; 2004 Feb; 19(4):455-62. PubMed ID: 14871286
[TBL] [Abstract][Full Text] [Related]
10. Lansoprazole vs. omeprazole for gastro-oesophageal reflux disease: a pH-metric comparison.
Frazzoni M; De Micheli E; Grisendi A; Savarino V
Aliment Pharmacol Ther; 2002 Jan; 16(1):35-9. PubMed ID: 11856076
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease.
Janczewska I; Sagar M; Sjöstedt S; Hammarlund B; Iwarzon M; Seensalu R
Scand J Gastroenterol; 1998 Dec; 33(12):1239-43. PubMed ID: 9930385
[TBL] [Abstract][Full Text] [Related]
12. Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease.
Kahrilas PJ; Hughes N; Howden CW
Gut; 2011 Nov; 60(11):1473-8. PubMed ID: 21508423
[TBL] [Abstract][Full Text] [Related]
13. Effects of long-term treatment with proton pump inhibitors in gastro-oesophageal reflux disease on the histological findings in the lower oesophagus.
Stolte M; Vieth M; Schmitz JM; Alexandridis T; Seifert E
Scand J Gastroenterol; 2000 Nov; 35(11):1125-30. PubMed ID: 11145281
[TBL] [Abstract][Full Text] [Related]
14. An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy.
Nzeako UC; Murray JA
Aliment Pharmacol Ther; 2002 Jul; 16(7):1309-16. PubMed ID: 12144581
[TBL] [Abstract][Full Text] [Related]
15. Does short-term treatment with proton pump inhibitors cause rebound aggravation of symptoms?
Farup PG; Juul-Hansen PH; Rydning A
J Clin Gastroenterol; 2001 Sep; 33(3):206-9. PubMed ID: 11500608
[TBL] [Abstract][Full Text] [Related]
16. Night-time gastro-oesophageal reflux disease: prevalence, hazards, and management.
Orr WC
Eur J Gastroenterol Hepatol; 2005 Jan; 17(1):113-20. PubMed ID: 15647651
[TBL] [Abstract][Full Text] [Related]
17. Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial.
Schwizer W; Thumshirn M; Dent J; Guldenschuh I; Menne D; Cathomas G; Fried M
Lancet; 2001 Jun; 357(9270):1738-42. PubMed ID: 11403809
[TBL] [Abstract][Full Text] [Related]
18. Lansoprazole: in the treatment of gastro-oesophageal reflux disease in children and adolescents.
Croom KF; Scott LJ
Drugs; 2005; 65(15):2129-35; discussion 2136-7. PubMed ID: 16225368
[TBL] [Abstract][Full Text] [Related]
19. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease.
Richter JE; Campbell DR; Kahrilas PJ; Huang B; Fludas C
Arch Intern Med; 2000 Jun; 160(12):1803-9. PubMed ID: 10871974
[TBL] [Abstract][Full Text] [Related]
20. Laparoscopic fundoplication versus lansoprazole for gastro-oesophageal reflux disease. A pH-metric comparison.
Frazzoni M; Grisendi A; Lanzani A; Melotti G; De Micheli E
Dig Liver Dis; 2002 Feb; 34(2):99-104. PubMed ID: 11926567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
